- Trials with a EudraCT protocol (100)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
100 result(s) found for: Virus replication.
Displaying page 1 of 5.
EudraCT Number: 2012-003312-30 | Sponsor Protocol Number: 2012-24 | Start Date*: 2012-12-12 |
Sponsor Name:ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE | ||
Full Title: Interest of preemptive treatment with ganciclovir or acyclovir in patients requiring prolonged mechanical ventilation and have either a cytomegalovirus replication in blood or an herpes simplex vir... | ||
Medical condition: mechanically ventilated patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-000849-50 | Sponsor Protocol Number: MI-CP114 | Start Date*: 2017-12-12 |
Sponsor Name:MedImmune | ||
Full Title: A Phase I Randomized, Double-Blind Trial of the Safety and Immunogenicity of FluMist® A Live, Intranasal Influenza Virus Vaccine vs. Placebo in Immunocompromised Children Ages 5 Through 17 Years of... | ||
Medical condition: The prevention of Influenza Virus in Immunocompromised children ages 5 through 17 years of age. | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2011-002267-26 | Sponsor Protocol Number: 13071981 | Start Date*: 2012-04-12 | |||||||||||
Sponsor Name:Medizinische Universität Wien | |||||||||||||
Full Title: Hepatitis C in renal transplant recipients – Safety and efficacy of a conversion of immunosuppression to high-dose cyclosporine A and its impact on HCV-replication, parameters of liver function and... | |||||||||||||
Medical condition: renal transplant recipients with hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001461-32 | Sponsor Protocol Number: ITATI | Start Date*: 2019-10-25 | |||||||||||
Sponsor Name:IrsiCaixa AIDS Research Institute | |||||||||||||
Full Title: Immune Therapy and Analytical Treatment Interruption in HIV+ participants who received an allogeneic stem cell transplantation (ITATI) | |||||||||||||
Medical condition: HIV+ infected subjects with undetectable replication competent HIV reservoir after allogeneic stem cell transplantation in presence of cART. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011273-32 | Sponsor Protocol Number: 149/09 | Start Date*: 2009-05-07 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: Pilot study for the evaluation of the safety and the feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in patients on stable treatment with two NRTIs + atazanavir/ritonav... | |||||||||||||
Medical condition: HIV | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-002978-35 | Sponsor Protocol Number: HLS05/2008 | Start Date*: 2008-07-24 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE) | |||||||||||||
Full Title: Intensification of HAART with Maraviroc (MVC) as first line therapy of HIV-1-infected patients to rapidly suppress viral replication and minimize the evolution of drug-resistant variants | |||||||||||||
Medical condition: First line therapy of HIV-1-infected patients. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000836-27 | Sponsor Protocol Number: AI444-026 | Start Date*: 2011-09-30 | |||||||||||
Sponsor Name:Bristol Myers Squibb International Corporation | |||||||||||||
Full Title: An Open-Label Re-treatment Study with Peg-Interferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C Revised Protocol Number 05; Incorporates Ame... | |||||||||||||
Medical condition: HEPATITIS C VIRUS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) GB (Completed) ES (Completed) SE (Completed) DK (Completed) IT (Completed) AT (Completed) NL (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000240-94 | Sponsor Protocol Number: CLEAR0001 | Start Date*: 2012-05-09 | ||||||||||||||||
Sponsor Name:Aarhus University Hospital | ||||||||||||||||||
Full Title: The Safety and Efficacy of The Histone Deacetylase Inhibitor Panobinostat for Purging HIV-1 from The Latent Reservoir (CLEAR) Study | ||||||||||||||||||
Medical condition: Human Immunodeficiency Virus (HIV) Infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-003136-22 | Sponsor Protocol Number: GS-US-174-0106 | Start Date*: 2006-05-05 | |||||||||||
Sponsor Name:Gilead Sciences Incorporated | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind Study Exploring the Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine plus Tenofovir DF Fixed-Dose Combina... | |||||||||||||
Medical condition: Chronic Hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000685-42 | Sponsor Protocol Number: 2DR-study | Start Date*: 2020-04-30 |
Sponsor Name:Ghent University Hospital | ||
Full Title: Virological and immunological assessment in HIV positive participants on 2DR versus 3DR in a prospective randomized controlled switch trial. | ||
Medical condition: human immunodeficiency viruses (HIV) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Trial now transitioned) | ||
Trial results: View results |
EudraCT Number: 2011-003067-30 | Sponsor Protocol Number: AI444-043 | Start Date*: 2012-01-11 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 3, Open Label Study of Safety and Efficacy with BMS-790052 plus Peg-Interferon Alfa 2a and Ribavirin in Previously Untreated HCV Patients Coinfected with Human Immunodeficiency Virus (HIV) ... | |||||||||||||
Medical condition: Chronic Hepatitis C / HIV-1 co-infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) GB (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001288-26 | Sponsor Protocol Number: DASAHIVCURE | Start Date*: 2022-08-18 | |||||||||||
Sponsor Name:IDIBAPS | |||||||||||||
Full Title: Safety, tolerance and antiretroviral activity of dasatinib: a pilot clinical trial in patients with recent HIV-1 infection | |||||||||||||
Medical condition: Recent HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003201-81 | Sponsor Protocol Number: GFVT01026904 (GACHE) | Start Date*: 2006-12-20 |
Sponsor Name:Universitätsklinikum Heidelberg | ||
Full Title: GACHE: German trial of Acyclovir and Corticosteroids in Herpes-simplex-virus-Encephalitis. A multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial. | ||
Medical condition: Herpes simplex virus type-1 (HSV-1) is the most frequent cause of fatal sporadic encephalitis in humans. Herpes simplex encephalitis (HSE) was one of the first viral infections to be successfully t... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-004138-41 | Sponsor Protocol Number: TEL-PR | Start Date*: 2012-12-10 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI PARMA | |||||||||||||
Full Title: Anti-viral T cell responses in patients with chronic HCV infection treated with telaprevir: can therapy induce functional T cell reconstitution? | |||||||||||||
Medical condition: Chronic active hepatitis C never treated previously with anti-HCV therapies | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024496-37 | Sponsor Protocol Number: 1716-12 | Start Date*: 2012-05-04 | |||||||||||
Sponsor Name:Virttu Biologics Limited | |||||||||||||
Full Title: A PHASE I/IIa STUDY OF THE SAFETY, TOLERABILITY AND BIOLOGICAL EFFECT OF SINGLE AND REPEAT ADMINISTRATION OF THE SELECTIVELY REPLICATION-COMPETENT HERPES SIMPLEX VIRUS HSV1716 INTO THE TUMOUR-BEAR... | |||||||||||||
Medical condition: Malignant Pleural Mesothelioma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003951-13 | Sponsor Protocol Number: ANRS177DUETTO | Start Date*: 2021-04-19 | |||||||||||
Sponsor Name:INSERM-ANRS | |||||||||||||
Full Title: Randomized, open-label and multicentric trial evaluating the non-inferiority of antiretroviral dual therapy taken 4 consecutive days per week versus antiretroviral dual therapy 7/7 days per week in... | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004464-30 | Sponsor Protocol Number: RIPIM | Start Date*: 2011-11-22 | |||||||||||
Sponsor Name:Institut de Recerca e la SIDA - IrsiCaixa- | |||||||||||||
Full Title: Impact of Raltegravir Intensification on HIV-1-infected Subjects with Complete Viral Suppression under Monotherapy with Protease Inhibitors. A 24-week controlled, open-label, proof-of-concept pilot... | |||||||||||||
Medical condition: HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001789-34 | Sponsor Protocol Number: OptiB2007 | Start Date*: 2007-10-05 | |||||||||||
Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA | |||||||||||||
Full Title: A multicenter open label study to explore the efficacy and tolerability of Tenofovir DF (TDF) (300 mg) in chronic hepatitis B, HBeAg positive or negative, patients with suboptimal response to adefo... | |||||||||||||
Medical condition: Chronic Hepatitis B HBV | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005238-23 | Sponsor Protocol Number: MCA-896 | Start Date*: 2016-10-18 | ||||||||||||||||
Sponsor Name:Rockefeller University | ||||||||||||||||||
Full Title: A phase 2a, randomized study of the combination of romidepsin and 3BNC117 to evaluate the effects on the HIV-1 reservoir (ROADMAP) | ||||||||||||||||||
Medical condition: HIV infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Prematurely Ended) DE (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-007296-24 | Sponsor Protocol Number: 08/01 | Start Date*: 2009-01-21 | |||||||||||
Sponsor Name:AISF - ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO | |||||||||||||
Full Title: Multicenter open-label, phase IIB study with 0.5 mg / day Entecavir (BARACLUDE ) in patients with positive HBsAg solid or hematologic malignancies undergoing chemotherapy (ChemET) (ChemET) | |||||||||||||
Medical condition: Subject with new diagnosis of solid or haematological cancer in inactive carrier in chronic virus B infected patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
